Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen receptor (ER),progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) expressions.TNBC is invalid for endocrine therapy and anti-HER-2 therapy.TNBC is a heterogeneous breast cancer group and lacks of effective molecular targets.As its unique clinical pathological features with high rate of invasion and metastasis,recurrence,and unfavorable prognosis,exploring the clinicopathological features and molecular markers is necessary for clinical diagnosis and treatment of TNBC patients.%三阴乳腺癌(triple-negative breast cancer,TNBC)即雌激素受体(estrogen receptor,ER)、孕激素受体(progestogen receptor,PR)、人表皮生长因子受体-2(human epithelial growth factor receptor-2,HER-2)均为阴性的乳腺癌.对内分泌治疗和抗HER-2的治疗无效,其分子亚型较多,存在基因表达差异,异质性明显,缺乏有效的分子靶标,且具有较高的侵袭转移率及复发率、预后差,临床病理学特征独特,因此探寻TNBC的临床病理特征及其分子标志物,对临床进一步诊断及治疗TNBC具有重要意义.
展开▼
